This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It answers the most basic questions from a patient’s perspective
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
